BioSpace News Archive

MammaPrint was the only test to predict significant 36% and 52% reductions in DFS and BCFI events, respectively, for patients treated with extended endocrine therapy

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it has initiated a sheep study to investigate MN-166 in an ovine model of chlorine-induced acute lung injury.

Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced the administration of the first dose of FW-1022 to a volunteer in the ongoing Phase 2 RESERVOIR clinical trial.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, announced that a peer-reviewed publication of a case series report of basal cell carcinoma destruction by a concentrate of proteolytic enzymes enriched in bromelain has been published in the Open Dermatology Journal.

Single-dose administration of IN8bio’s genetically modified gamma delta T-cells in lymphodepleted glioblastoma multiforme (GBM) patients was well tolerated

Professor Gemma Figtree at The University of Sydney and her multi-disciplinary team have been awarded AU$1.4 million by the National Health and Medical Research Council (NHMRC) Partnership Projects as part of a collaborative effort between academics and policy makers in Australia .

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced that it has submitted an updated 510 summary document to the U.S. FDA for its Acuitas AMR Gene Panel for Isolates.

-- $50 million milestone payment to be received this month for successful manufacturing, release, and delivery of clinical drug product to support influenza mRNA vaccine clinical trial anticipated to begin in the coming weeks --